Breaking News Instant updates and real-time market news.

SMMT

Summit Therapeutics

$14.35

5.7 (65.90%)

, SRPT

Sarepta

$61.48

0.53 (0.87%)

07:59
10/05/16
10/05
07:59
10/05/16
07:59

Summit Therapeutics price target raised to $28 from $14 at Canaccord

Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.

SMMT

Summit Therapeutics

$14.35

5.7 (65.90%)

SRPT

Sarepta

$61.48

0.53 (0.87%)

  • 06

    Nov

SMMT Summit Therapeutics
$14.35

5.7 (65.90%)

10/04/16
JMPS
10/04/16
NO CHANGE
JMPS
Outperform
Summit Therapeutics price target raised to $42 from $24 at JMP Securities
10/04/16
NEED
10/04/16
NO CHANGE
Target $30
NEED
Buy
Summit Therapeutics price target raised to $30 from $22 at Needham
Sarepta Therapeutics (SRPT) and Summit Therapeutics (SMMT) announced this morning that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States, to Summit's utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
09/16/16
HCWC
09/16/16
INITIATION
Target $26
HCWC
Buy
Summit Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther initiated Summit Therapeutics with a Buy and a $26 price target saying Ezutromid in DMD can potentially generate $1.2B in global sales in FY26.
SRPT Sarepta
$61.48

0.53 (0.87%)

09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.
09/23/16
PIPR
09/23/16
NO CHANGE
Target $64
PIPR
Overweight
Sarepta stock issuance strengthens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Sarepta Therapeutics has a strengthened balance sheet after issuing 5.02M shares at a price of $59.75. Further, for its Exondys51 approval, Sarepta gained a Rare Priority Review Voucher that could be sold to further pad the company's cash position, Tenthoff tells investors in an intraday research note. He reiterates an Overweight rating on the shares with a $64 price target. The stock is down 5% to $57.74 in late afternoon trading.

TODAY'S FREE FLY STORIES

PH

Parker-Hannifin

$161.98

-2.56 (-1.56%)

08:15
04/28/17
04/28
08:15
04/28/17
08:15
Recommendations
Parker-Hannifin analyst commentary  »

Parker-Hannifin price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
U.S. Q1 GDP preview: »

U.S. Q1 GDP preview:…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
Employment Cost Index ECI to be reported at 08:30 »

Employment Cost Index ECI…

08:15
04/28/17
04/28
08:15
04/28/17
08:15
General news
GDP price index to be reported at 08:30 »

GDP price index will be…

DB

Deutsche Bank

$18.15

-0.69 (-3.66%)

, C

Citi

$59.39

-0.55 (-0.92%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Hot Stocks
Deutsche Bank confirms James von Moltke to succeed Marcus Schenck as CFO »

Deutsche Bank's (DB)…

DB

Deutsche Bank

$18.15

-0.69 (-3.66%)

C

Citi

$59.39

-0.55 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 25

    Jul

WDC

Western Digital

$85.71

1.1 (1.30%)

08:14
04/28/17
04/28
08:14
04/28/17
08:14
Downgrade
Western Digital rating change  »

Western Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$918.38

9.09 (1.00%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Recommendations
Amazon.com analyst commentary  »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 16

    May

  • 23

    May

LH

LabCorp

$139.68

0.99 (0.71%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Hot Stocks
LabCorp to exclusively offer M3 Checklist for mental illness »

LabCorp and M-3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

ATTO

Atento

$8.85

-0.1 (-1.12%)

08:13
04/28/17
04/28
08:13
04/28/17
08:13
Earnings
Atento announces prepayment of $27M Brazilian debentures »

Atento made a $26.7M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 11

    May

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Conference/Events
Cowen analysts hold an analyst/industry conference call »

Analysts provide an…

TER

Teradyne

$36.35

2.58 (7.64%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Teradyne analyst commentary  »

Teradyne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

  • 21

    Jun

EXPE

Expedia

$136.20

0.45 (0.33%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
Expedia analyst commentary  »

Expedia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

LLL

L3 Technologies

$173.94

2.18 (1.27%)

08:12
04/28/17
04/28
08:12
04/28/17
08:12
Recommendations
L3 Technologies analyst commentary  »

L3 Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

, SYK

Stryker

$135.37

-0.82 (-0.60%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Downgrade
Zimmer Biomet, Stryker rating change  »

Zimmer Biomet downgraded…

ZBH

Zimmer Biomet

$118.10

-7.22 (-5.76%)

SYK

Stryker

$135.37

-0.82 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 04

    May

PTEN

Patterson-UTI

$21.93

-1.07 (-4.65%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Recommendations
Patterson-UTI analyst commentary  »

Patterson-UTI weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

MGA

Magna

$41.40

0.56 (1.37%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Magna enters joint venture with Chinese seating supplier »

Magna has entered into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

  • 11

    May

XOM

Exxon Mobil

$81.26

-0.14 (-0.17%)

08:11
04/28/17
04/28
08:11
04/28/17
08:11
Hot Stocks
Exxon Mobil says Q1 Chemical earnings impacted primarily by lower margins »

Exxon Mobil reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

RWLK

ReWalk Robotics

$1.45

-0.2 (-12.12%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
ReWalk Robotics names Jodi Gricci as Chief Commercial Officer »

ReWalk Robotics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

HON

Honeywell

$129.88

-0.22 (-0.17%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Periodicals
Honeywell talks with Third Point still friendly, CNBC's Faber says »

Talks between Honeywell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FSS

Federal Signal

$15.38

0.98 (6.81%)

08:10
04/28/17
04/28
08:10
04/28/17
08:10
Hot Stocks
Federal Signal awarded $128K of legal costs in hearing loss litigation »

Federal Signal announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.10

-0.0099 (-9.00%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Hot Stocks
CEL-SCI says European Patent office to grant new Multikine patent »

CEL-SCI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$33.05

-0.18 (-0.54%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Technical Analysis
Synchrony drops sharply after earnings miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 18

    May

  • 31

    May

MSFT

Microsoft

$68.27

0.44 (0.65%)

08:09
04/28/17
04/28
08:09
04/28/17
08:09
Recommendations
Microsoft analyst commentary  »

Microsoft commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

RCL

Royal Caribbean

$100.50

0.03 (0.03%)

08:08
04/28/17
04/28
08:08
04/28/17
08:08
Hot Stocks
Royal Caribbean sees FY17 CapEx $0.6B »

Based upon current ship…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.